78 related articles for article (PubMed ID: 9886175)
1. Expression of osteopontin and osteonectin in breast cancer.
Kim YW; Park YK; Lee J; Ko SW; Yang MH
J Korean Med Sci; 1998 Dec; 13(6):652-7. PubMed ID: 9886175
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
[TBL] [Abstract][Full Text] [Related]
3. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
4. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive factors of invasive ductal breast carcinomas.
Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
[TBL] [Abstract][Full Text] [Related]
6. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
Hsiao YH; Lien HC; Hwa HL; Kuo WH; Chang KJ; Hsieh FJ
Breast J; 2010; 16(3):305-8. PubMed ID: 20210803
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast.
Tökés AM; Hortoványi E; Csordás G; Kulka J; Mózes G; Hatalyák A; Kádár A
Anticancer Res; 1999; 19(1A):175-9. PubMed ID: 10226540
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
12. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
[TBL] [Abstract][Full Text] [Related]
13. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci.
Hirota S; Ito A; Nagoshi J; Takeda M; Kurata A; Takatsuka Y; Kohri K; Nomura S; Kitamura Y
Lab Invest; 1995 Jan; 72(1):64-9. PubMed ID: 7837792
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
15. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
16. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
17. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
Meenakshi A; Manoharan V
Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
[TBL] [Abstract][Full Text] [Related]
18. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
[TBL] [Abstract][Full Text] [Related]
20. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.
Wang-Rodriguez J; Urquidi V; Rivard A; Goodison S
Breast Cancer Res; 2003; 5(5):R136-43. PubMed ID: 12927044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
